PD-1 Non-Small Cell Lung Cancer (PD-1+ NSCLC) - Pipeline Insight, 2024

PD-1 Non-Small Cell Lung Cancer (PD-1+ NSCLC) - Pipeline Insight, 2024

DelveInsight’s, “PD-1 Non-Small Cell Lung Cancer (PD-1+ NSCLC) - Pipeline Insight, 2024” report provides comprehensive insights about 25+ companies and 30+ pipeline drugs in PD-1 Non-Small Cell Lung Cancer (PD-1+ NSCLC) pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

Global coverage

PD-1 Non-Small Cell Lung Cancer (PD-1+ NSCLC): Understanding

PD-1 Non-Small Cell Lung Cancer (PD-1+ NSCLC): Overview

Lung cancer remains a leading cause of cancer-related mortality worldwide with the poor prognosis. Encouragingly, immune checkpoint blockade targeting programmed death-1 (PD-1) and programmed death-ligand 1 (PD-L1) has dramatically changed the landscape for treatments in patients with non-small-cell lung cancer (NSCLC). Blockade of programmed death-1 (PD-1) receptor and its ligand PD-L1 has achieved robust responses and improved survival for patients with locally advanced/metastatic NSCLC in preclinical and clinical studies. InPD-1 is a Type I transmembrane protein and is expressed on T-cells, B-cells, nature killer cells, activated monocytes, and dendritic cells (DCs). PD-L1 and PD-L2, two ligands of PD-1, are also Type I transmembrane proteins and differ in their expression patterns. PD-L1 can be expressed on T-cells, B-cells, DCs, macrophages, a wide variety of nonhematopoietic cells, and also on TCs.11–13 PD-1 and its ligands consist of a signal sequence.

immunoglobulin (Ig) domain and transmembrane domains, and a short cytoplasmic tail. PD-1 is phosphorylated on its two intracellular tyrosines after PD-1 binding to PD-L1 or PD-L2 based on their IgV-like domain. Then PD-1 binds two phosphatases, SHP-1 and SHP-2, which can bind to the ITIM and ITSM motifs of PD-1, which will downregulate antigen receptor signaling.11,14,15 The engagement of PD-1 by PD-L1 and PD-L2 inhibits the function of effector T-cells, while the engagement of B7-1/B7-2 and its ligand CD28 simulate T-cells proliferation.

CDKs and cyclins appear and activate at specific cell cycle phases. Seven PD-1 Non-Small Cell Lung Cancer (PD-1+ NSCLC) proteins have been identified. They are p15, p16, p18, p19, p21, p27, and p57. These PD-1 Non-Small Cell Lung Cancer (PD-1+ NSCLC) protein emerges only in their specific cell cycle phase. Each Cyclin/CDK complex are specific to the part of the cell cycle phase. Each CDK and cyclin can be identified based on the location of the cell cycle. CKIs fall within two categories; those that inhibit CDKI, CDK2, and CDK5 and those that inhibit CDK4 and CDK6. Targeting the PD-1/PD-L1 signaling pathway has recently become a promising therapeutic strategy in cancer therapy. Such a strategy is through a mechanism by preventing the escape of tumor cells from the immune surveillance and restoring the function of the host's immune system to attack the tumor cells.

“PD-1 Non-Small Cell Lung Cancer (PD-1+ NSCLC) - Pipeline Insight, 2024"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the mechanism of action. A detailed picture of the PD-1 Non-Small Cell Lung Cancer (PD-1+ NSCLC) pipeline landscape is provided which includes the disease overview and PD-1 Non-Small Cell Lung Cancer (PD-1+ NSCLC) treatment guidelines. The assessment part of the report embraces, in depth PD-1 Non-Small Cell Lung Cancer (PD-1+ NSCLC) commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, PD-1 Non-Small Cell Lung Cancer (PD-1+ NSCLC) collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence PD-1 Non-Small Cell Lung Cancer (PD-1+ NSCLC) R&D. The therapies under development are focused on novel approaches to treat/improve PD-1 Non-Small Cell Lung Cancer (PD-1+ NSCLC).

PD-1 Non-Small Cell Lung Cancer (PD-1+ NSCLC) Emerging Drugs Chapters

This segment of the PD-1 Non-Small Cell Lung Cancer (PD-1+ NSCLC) report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

PD-1 Non-Small Cell Lung Cancer (PD-1+ NSCLC) Emerging Drugs

Zimberelimab: Arcus Biosciences

Zimberelimab is an anti-programmed cell death protein-1 (PD-1) monoclonal antibody being developed by Gloria Biosciences, Arcus Biosciences and Taiho Pharmaceutical Co. for the treatment of various cancers including cervical cancer, non-small cell lung cancer and classical Hodgkin's lymphoma. Based on the results of a phase II trial, zimberelimab was recently approved for marketing in China as treatment for relapsed or refractory classical Hodgkin's lymphoma. Zimberelimab was in-licensed by Arcus to enable the development of precision combination regimens with full line-of-sight to the commercialization of innovative therapies for all patients who may benefit. The most advanced study with zimberelimab is in Phase III development for the treatment of first-line metastatic non-small cell lung cancer, evaluating zimberelimab in combination with domvanalimab, an anti-TIGIT monoclonal antibody, and etrumadenant, the first and only dual A2a/A2b adenosine receptor antagonist in the clinic.

PM8002: Biotheus

PM8002 is a bispecific antibody candidate with humanized anti-PD-L1 single heavy-chain variable (VHH) domains fused to an anti-VEGF-A IgG1 antibody containing Fc-silencing mutations. PM8002 had demonstrated a positive safety profile and encouraging antitumor activity presumably through reduced systemic toxicity by enriching anti-VEGF activity into the tumor microenvironment at ASCO Annual Meeting and ESMO Congress 2023. Currently, the drug is in Phase II/III stage of its clinical trial for the treatment of NSCLC.

RPH075: R-Pharm

R-Pharm's pembrolizumab biosimilar, known as RPH 075, is a monoclonal antibody classified under antineoplastics, antivirals, and immunotherapies, specifically tumor-agnostic therapies. This biosimilar mimics the action of the originator drug, pembrolizumab, by targeting and antagonizing the programmed cell death 1 (PD-1) receptor on T lymphocytes. By blocking the interaction between PD-1 and its ligands, RPH 075 enhances T-cell mediated immune responses against cancer cells, promoting antibody-dependent cell cytotoxicity and providing a potent means to counteract tumors. Currently, the drug is in Phase I stage of its clinical trial for the treatment of NSCLC.

Further product details are provided in the report……..

PD-1 Non-Small Cell Lung Cancer (PD-1+ NSCLC): Therapeutic Assessment

This segment of the report provides insights about the different PD-1 Non-Small Cell Lung Cancer (PD-1+ NSCLC) drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in PD-1 Non-Small Cell Lung Cancer (PD-1+ NSCLC)

There are approx. 25+ key companies which are developing the therapies for PD-1 Non-Small Cell Lung Cancer (PD-1+ NSCLC). The companies which have their PD-1 Non-Small Cell Lung Cancer (PD-1+ NSCLC) drug candidates in the most advanced stage, i.e. Phase III include, Arcus Biosciences.

Phases

DelveInsight’s report covers around 30+ products under different phases of clinical development like

Late stage products (Phase III)

Mid-stage products (Phase II)

Early-stage product (Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

PD-1 Non-Small Cell Lung Cancer (PD-1+ NSCLC) pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Intra-articular

Intraocular

Intrathecal

Intravenous

Oral

Parenteral

Subcutaneous

Topical

Transdermal

Molecule Type

Products have been categorized under various Molecule types such as

Oligonucleotide

Peptide

Small molecule

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

PD-1 Non-Small Cell Lung Cancer (PD-1+ NSCLC): Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses PD-1 Non-Small Cell Lung Cancer (PD-1+ NSCLC) therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging PD-1 Non-Small Cell Lung Cancer (PD-1+ NSCLC) drugs.

PD-1 Non-Small Cell Lung Cancer (PD-1+ NSCLC) Report Insights

PD-1 Non-Small Cell Lung Cancer (PD-1+ NSCLC) Pipeline Analysis

Therapeutic Assessment

Unmet Needs

Impact of Drugs

PD-1 Non-Small Cell Lung Cancer (PD-1+ NSCLC) Report Assessment

Pipeline Product Profiles

Therapeutic Assessment

Pipeline Assessment

Inactive drugs assessment

Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

How many companies are developing PD-1 Non-Small Cell Lung Cancer (PD-1+ NSCLC) drugs?

How many PD-1 Non-Small Cell Lung Cancer (PD-1+ NSCLC) drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for the treatment of PD-1 Non-Small Cell Lung Cancer (PD-1+ NSCLC)?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the PD-1 Non-Small Cell Lung Cancer (PD-1+ NSCLC) therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for PD-1 Non-Small Cell Lung Cancer (PD-1+ NSCLC) and their status?

What are the key designations that have been granted to the emerging drugs?

Key Players

Arcus Biosciences

Akeso Biopharma

Biotheus

GlaxoSmithKline

AstraZeneca

Pfizer

Shandong Boan Biotechnology

Genor Biopharma

Key Products

Zimberelimab

AK-112

PM 8002

Dostarlimab

AZD2936

PF-06801591

BA-1104

GB226